Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04478071 · ClinicalTrials.gov registry record · Phase 2
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 448
- Enrollment target
NCT04478071 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 448 participants.
The verdict
NCT04478071, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 448 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).
Interventions
- DRUG placebo
- DRUG vadadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 448 participants |
| Start Date | 2020-08-22 |
| Est. Completion | 2022-03-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04478071
The ClinicalTrials.gov registry entry for NCT04478071 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 448 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT04478071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04478071 about?
NCT04478071 is a clinical study titled "Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)". The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).
What is the current status of trial NCT04478071?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 448 participants. The study started on 2020-08-22. Estimated completion is 2022-03-25.
What interventions are being tested in trial NCT04478071?
The interventions under investigation include: placebo (DRUG), vadadustat (DRUG).
Who is sponsoring clinical trial NCT04478071?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.